Abstract:Background: Osteoarthritis (OA) is a highly debilitating, degenerative pathology of cartilaginous joints affecting over 500 million people worldwide. The global economic burden of OA is estimated at $260-519 billion and growing, driven by aging global population and increasing rates of obesity. To date, only the multi-injection chondroanabolic treatment regimen of Fibroblast Growth Factor 18 (FGF18) has demonstrated clinically meaningful disease-modifying efficacy in placebo-controlled human trials. Our work focuses on the development of a novel single injection disease-modifying gene therapy, based on FGF18's chondroanabolic activity. Methods: OA was induced in Sprague-Dawley rats using destabilization of the medial meniscus (DMM) (3 weeks), followed by intra-articular treatment with 3 dose levels of AAV2-FGF18, rh- FGF18 protein, and PBS. Durability, redosability, and biodistribution were measured by quantifying nLuc reporter bioluminescence. Transcriptomic analysis was performed by RNA-seq on cultured human chondrocytes and rat knee joints. Morphological analysis was performed on knee joints stained with Safranin O/Fast Green and anti-PRG antibody. Results: Dose-dependent reductions in cartilage defect size were observed in the AAV2-FGF18- treated joints relative to the vehicle control. Total defect width was reduced by up to 76% and cartilage thickness in the thinnest zone was increased by up to 106%. Morphologically, the vehicle- treated joints exhibited pronounced degeneration, ranging from severe cartilage erosion and bone void formation, to subchondral bone remodeling and near-complete subchondral bone collapse. In contrast, AAV2-FGF18-treated joints appeared more anatomically normal, with only regional glycosaminoglycan loss and marginal cartilage erosion. While effective at reducing cartilage lesions, treatment with rhFGF18 injections resulted in significant joint swelling (19% increase in diameter), as well as a decrease in PRG4 staining uniformity and intensity. In contrast to early-timepoint in vitro RNA-seq analysis, which showed a high degree of concordance between protein- and gene therapy-treated chondrocytes, in vivo transcriptomic analysis, revealed few gene expression changes following protein treatment. On the other hand, the gene therapy treatment exhibited a high degree of durability and localization over the study period, upregulating several chondroanabolic genes while downregulating OA- and fibrocartilage-associated markers. Conclusion: FGF18 gene therapy treatment of OA joints can provide benefits to both cartilage and subchondral bone, with a high degree of localization and durability.

Suppressing UPR-dependent Overactivation of FGFR3 Signaling Ameliorates SLC26A2-deficient Chondrodysplasias.

Targeting FGFR3 Signaling and Drug Repurposing for the Treatment of SLC26A2-related Chondrodysplasia in Mouse Model

Molecular therapeutic strategies for FGFR3 gene-related skeletal dysplasia

Biallelic variants in SLC26A2 cause multiple epiphyseal dysplasia-4 by disturbing chondrocyte homeostasis

Mutant Activated FGFR3 Impairs Endochondral Bone Growth by Preventing SOX9 Downregulation in Differentiating Chondrocytes.

A Ser(365)-->Cys Mutation of Fibroblast Growth Factor Receptor 3 in Mouse Downregulates Ihh/PTHrP Signals and Causes Severe Achondroplasia.

Suppression of heterotopic ossification in fibrodysplasia ossificans progressiva using AAV gene delivery

Gly369Cys Mutation in Mouse FGFR3 Causes Achondroplasia by Affecting Both Chondrogenesis and Osteogenesis.

A Lys644Glu Substitution in Fibroblast Growth Factor Receptor 3 (FGFR3) Causes Dwarfism in Mice by Activation of STATs and Ink4 Cell Cycle Inhibitors.

FGD1 Variant Associated with Aarskog–Scott Syndrome

Conditional inactivation of the L-type amino acid transporter LAT1 in chondrocytes models idiopathic scoliosis in mice

Defective Lysosomal Targeting of Activated Fibroblast Growth Factor Receptor 3 in Achondroplasia.

Phenotypic Characterization of Slc26a2 Mutant Mice Reveals a Multifactorial Etiology of Spondylolysis.

Melatonin Ameliorates Slc26a2-associated Chondrodysplasias by Attenuating Endoplasmic Reticulum Stress and Apoptosis of Chondrocytes

FGFR3 Induces Degradation of BMP Type I Receptor to Regulate Skeletal Development.

SHP2 ablation mitigates osteoarthritic cartilage degeneration by promoting chondrocyte anabolism through SOX9

Endoplasmic Reticulum Stress-Unfolding Protein Response-Apoptosis Cascade Causes Chondrodysplasia in a Col2a1 P.gly1170ser Mutated Mouse Model.

Novel NPR2 Gene Mutations Affect Chondrocytes Function Via ER Stress in Short Stature

Single Injection AAV2-FGF18 Gene Therapy Reduces Cartilage Loss and Subchondral Bone Damage in a Mechanically Induced Model of Osteoarthritis

A novel frameshift deletion variant of ARSL associated with X-linked recessive chondrodysplasia punctata 1: a case report and literature review of prenatal, confirmed cases

A novel FGFR3-binding peptide inhibits FGFR3 signaling and reverses the lethal phenotype of mice mimicking human thanatophoric dysplasia.